Septerna, Inc. (NASDAQ:SEPN) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Septerna, Inc. (NASDAQ:SEPN) have earned an average recommendation of “Moderate Buy” from the ten ratings firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $43.1250.

A number of research analysts recently issued reports on SEPN shares. Stifel Nicolaus assumed coverage on shares of Septerna in a research note on Friday, May 1st. They issued a “buy” rating and a $43.00 price objective on the stock. Wells Fargo & Company raised their target price on Septerna from $28.00 to $48.00 and gave the company an “overweight” rating in a report on Tuesday, March 3rd. Truist Financial lifted their price target on Septerna from $34.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday, March 11th. JPMorgan Chase & Co. boosted their price target on Septerna from $34.00 to $38.00 and gave the stock an “overweight” rating in a report on Tuesday, March 24th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $60.00 price objective on shares of Septerna in a research report on Tuesday, March 10th.

Septerna Stock Down 2.4%

SEPN opened at $26.30 on Thursday. The stock has a market capitalization of $1.19 billion, a price-to-earnings ratio of -32.47 and a beta of 2.21. Septerna has a twelve month low of $8.86 and a twelve month high of $32.63. The company has a 50-day simple moving average of $25.03 and a 200 day simple moving average of $25.57.

Septerna (NASDAQ:SEPN) last released its earnings results on Tuesday, May 12th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.23. The firm had revenue of $26.52 million for the quarter, compared to analyst estimates of $16.98 million. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. Sell-side analysts anticipate that Septerna will post -1.61 EPS for the current fiscal year.

Insider Activity

In other news, COO Elizabeth Bhatt sold 4,000 shares of the stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $24.34, for a total value of $97,360.00. Following the completion of the transaction, the chief operating officer owned 174,209 shares of the company’s stock, valued at approximately $4,240,247.06. This represents a 2.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Samira Shaikhly sold 70,453 shares of Septerna stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $28.10, for a total transaction of $1,979,729.30. Following the sale, the insider directly owned 793 shares in the company, valued at $22,283.30. This trade represents a 98.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 78,453 shares of company stock valued at $2,192,969. Insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Woodline Partners LP boosted its holdings in shares of Septerna by 94.2% during the 1st quarter. Woodline Partners LP now owns 582,585 shares of the company’s stock valued at $3,373,000 after acquiring an additional 282,585 shares in the last quarter. Rhumbline Advisers increased its holdings in Septerna by 16.6% in the 1st quarter. Rhumbline Advisers now owns 23,318 shares of the company’s stock worth $135,000 after purchasing an additional 3,323 shares in the last quarter. Geode Capital Management LLC raised its position in Septerna by 19.1% in the second quarter. Geode Capital Management LLC now owns 487,956 shares of the company’s stock valued at $5,158,000 after purchasing an additional 78,316 shares during the last quarter. JPMorgan Chase & Co. raised its position in Septerna by 15.0% in the second quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock valued at $107,000 after purchasing an additional 1,315 shares during the last quarter. Finally, CW Advisors LLC acquired a new stake in shares of Septerna during the second quarter valued at about $133,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.